News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Johnson & Johnson Will Unveil New Rivaroxaban Results on Monday
November 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Johnson & Johnson sat out the blockbuster heart-drug era when cholesterol-lowering statins and blood-pressure pills fueled years of double-digit earnings growth in the pharmaceutical industry.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees
September 11, 2025
·
1 min read
·
Tristan Manalac
Immunology and inflammation
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
September 10, 2025
·
2 min read
·
Tristan Manalac